Acpharis

Executive Summary

Acpharis is a San Diego-based biotechnology company founded in 2020, specializing in computational tools for early-stage drug discovery. The company's proprietary platform integrates solvent mapping and protein-protein docking software to identify druggable binding sites and model protein complexes, with a primary focus on oncology and small molecule therapeutics. By offering both a software platform and customized modeling services, Acpharis aims to accelerate the hit identification and lead optimization phases for pharmaceutical researchers. As a privately held, pre-revenue entity with no disclosed pipeline or financing, Acpharis represents an early-stage investment opportunity in the computational drug discovery space, where its differentiation lies in the application of advanced molecular modeling to enhance target druggability assessments. The company's success will depend on its ability to secure partnerships, validate its technology in real-world projects, and scale its platform.

Upcoming Catalysts (preview)

• TBDStrategic Partnership Announcement with Pharma/Biotech40% success
• TBDSeries A Fundraising Round Close50% success
• TBDPublication of Platform Validation in Peer-Reviewed Journal60% success